Is Colgate-Palmolive Co. overvalued or undervalued?
2025-11-11 11:23:12As of 7 November 2025, the valuation grade for Colgate-Palmolive Co. has moved from fair to expensive, indicating that the company is overvalued. Key valuation ratios highlight this assessment, with a P/E ratio of 41, a Price to Book Value of 354.55, and an EV to EBITDA of 26.86. In comparison to peers, Procter & Gamble Co. has a P/E of 38.51 and an EV to EBITDA of 28.49, suggesting that Colgate-Palmolive's valuation is relatively high. The company's recent stock performance also reinforces this valuation perspective, as it has underperformed against the S&P 500 with a year-to-date return of -13.68% compared to the index's 14.40%. Overall, the combination of high valuation ratios and poor stock performance suggests that Colgate-Palmolive Co. is currently overvalued....
Read MoreIs Colgate-Palmolive Co. overvalued or undervalued?
2025-11-10 11:14:39As of 7 November 2025, the valuation grade for Colgate-Palmolive Co. moved from fair to expensive. The company appears overvalued based on its elevated valuation ratios, including a P/E ratio of 41, a Price to Book Value of 354.55, and an EV to EBITDA of 26.86. In comparison, Procter & Gamble Co. has a P/E of 38.51 and an EV to EBITDA of 28.49, indicating that Colgate-Palmolive is trading at a premium relative to its peer. Despite a strong ROE of 868.55% and a solid ROCE of 60.76%, these figures do not justify the high valuation ratios, suggesting that the stock may be priced too high given its performance metrics. Over the past year, Colgate-Palmolive has underperformed the S&P 500, with a return of -13.23% compared to the index's 12.65%, reinforcing the notion that the stock is currently overvalued....
Read MoreIs Colgate-Palmolive Co. overvalued or undervalued?
2025-11-09 11:08:10As of 7 November 2025, the valuation grade for Colgate-Palmolive Co. has moved from fair to expensive, indicating that the stock is overvalued. The company exhibits a P/E ratio of 41, a Price to Book Value of 354.55, and an EV to EBITDA of 26.86, all of which are significantly higher than its peers, such as Procter & Gamble Co., which has a P/E of 38.51 and an EV to EBITDA of 28.49. Given these metrics, Colgate-Palmolive Co. appears to be overvalued in comparison to its industry peers. Additionally, the stock has underperformed relative to the S&P 500, with a year-to-date return of -13.36% compared to the index's 14.40%, reinforcing the notion of overvaluation....
Read More
Colgate-Palmolive Co. Stock Hits New 52-Week Low at $74.62
2025-11-03 16:56:34Colgate-Palmolive Co. has hit a new 52-week low, with its stock price declining significantly over the past year. The company, categorized as a large-cap in the FMCG sector, has a market capitalization of nearly USD 120 billion and a high P/E ratio, but faces challenges in performance indicators.
Read More
Colgate-Palmolive Co. Stock Plummets to 52-Week Low of $75.38
2025-10-30 18:06:41Colgate-Palmolive Co. has hit a new 52-week low, with its stock price declining significantly over the past year. The company, categorized as a large-cap in the FMCG sector, has a market capitalization of nearly USD 120 billion and notable financial metrics, including a high P/E ratio and strong return on equity.
Read MoreIs Colgate-Palmolive Co. overvalued or undervalued?
2025-10-21 12:04:30As of 17 October 2025, the valuation grade for Colgate-Palmolive Co. moved from very expensive to fair. The company is currently fairly valued based on its valuation metrics. Key ratios include a P/E ratio of 41, an EV to EBITDA of 26.86, and a PEG ratio of 3.10. In comparison, Procter & Gamble Co. has a P/E of 38.51 and an EV to EBITDA of 28.49, indicating that Colgate-Palmolive is competitively positioned within its industry. Despite its fair valuation, Colgate-Palmolive has underperformed relative to the S&P 500, with a year-to-date return of -12.97% compared to the index's 13.30%. This underperformance over multiple periods, including a 1-year return of -21.30% against the S&P 500's 14.08%, suggests that while the stock is fairly valued, it may face challenges in generating positive returns in the near term....
Read More
Colgate-Palmolive Co. Experiences Revision in Stock Evaluation Amid Mixed Performance Metrics
2025-10-20 15:48:34Colgate-Palmolive Co. has recently adjusted its valuation, with a P/E ratio of 41 and a high price-to-book value of 354.55. Despite a decline in stock performance over the past year, its valuation metrics remain competitive compared to peers like Procter & Gamble, indicating a need for continued market analysis.
Read MoreIs Colgate-Palmolive Co. overvalued or undervalued?
2025-10-20 12:21:59As of 17 October 2025, the valuation grade for Colgate-Palmolive Co. moved from very expensive to fair. The company is currently fairly valued, with a P/E ratio of 41, an EV to EBITDA ratio of 26.86, and a PEG ratio of 3.10. In comparison, Procter & Gamble Co. has a P/E of 38.51 and an EV to EBITDA of 28.49, indicating that Colgate is competitively positioned within its industry. Despite the fair valuation, Colgate-Palmolive has experienced negative returns over the past year, with a decline of 21.30%, while the S&P 500 returned 14.08% during the same period. This stark contrast in performance suggests that while the stock may be fairly valued, it has underperformed relative to the broader market....
Read MoreIs Colgate-Palmolive Co. overvalued or undervalued?
2025-10-19 11:59:37As of 17 October 2025, the valuation grade for Colgate-Palmolive Co. moved from very expensive to fair. Based on the current metrics, the company appears fairly valued. Key ratios include a P/E ratio of 41, an EV to EBITDA of 26.86, and a PEG ratio of 3.10, which suggest that while the company is not undervalued, it is also not excessively priced compared to its peers. In comparison with its peers, Procter & Gamble Co. has a P/E ratio of 38.51 and an EV to EBITDA of 28.49, indicating that Colgate-Palmolive is slightly more expensive on a P/E basis but more favorable on the EV to EBITDA metric. Despite the fair valuation, Colgate-Palmolive has underperformed relative to the S&P 500 across multiple time frames, with a 1-year return of -21.30% compared to the S&P 500's 14.08%, highlighting potential concerns for investors....
Read More





